Posts by Sandra Ansanay-Alex
Forum EPFL + Startup Day
Forum EPFL is taking place from 6 to 10 October 2025 at the SwissTech Convention Center. In October 2025, the Forum EPFL celebrate ists 43rd anniversary and remains one of the biggest job fairs in Europe, improving its services on a yearly basis. The Forum’s goal is to facilitate the students’ transition between studies…
Read MoreNagi Bioscience secures CHF 12.4 Million Investment
Nagi Bioscience, a Swiss life sciences company developing next-generation laboratory equipment to unlock the full potential of alternatives to animal testing. The company announces the successful closure of its Series A funding round. It has secured an oversubscribed 12.4M CHF investment from top-tier venture capital firms across Europe, co- led by Swisscanto and…
Read MoreDebiopharm Innovation Fund: a new seed fund dedicated to Digital Health
Debiopharm Innovation Fund, the strategic investment arm of Swiss biopharmaceutical company Debiopharm, with $150 million under management, announces the launch of its new seed funding initiative. It plans to deploy additional capital to support up to 15 seed-stage startups each year. Building on its strong track record of investing in 25 companies since…
Read MoreAtinary Technologies raises CHF 4.6 Million
The Biopôle-based start-up has developed a machine learning platform dedicated to materials discovery. The seed-round was round led by AgFunder and supported by Cherubic Ventures. Atinary is dedicated to accelerating R&D and discovery across diverse industries, including pharmaceuticals, biotechnology, chemicals, energy, electronics, cosmetics, and food via its cutting-edge, no-code platform SDLabs. This investment will…
Read MoreFuture Health Grant – 9 new projects selected
This great Swiss Health Valley🇨🇭 initiative was started by CSS and EPFL Innovation Park to promote Medicine 3.0. The 9 projects of the new cohort will receive between CHF 10,000 and CHF 50,000 as well as support and coaching. Allians Allergy Allergix – Digital solution enabling healthcare professionals to protect their patients against…
Read MoreFuture Health Lausanne, an opportunity for the Swiss Health Valley
Future Health Lausanne is taking place on 3 October 2023 at the Swisstech Convention Center in Lausanne. The event is a real opportunity to bring together the regional life sciences ecosystem according to Magali Bischof, BioAlps’ Secretary General. Tell us more about the translation ecosystem in the region? The Swiss Health Valley is home…
Read MoreAdiposs SA announced the completion of the phase I clinical trial of its ImageBAT™
Adiposs SA, a Swiss biotech company developing medical imaging products and technologies, announced the completion of the phase I clinical trial of its flagship product, ImageBAT™, a medical imaging product Thirty healthy subjects were given single ascending doses of ImageBAT™. The product demonstrated good tolerability and safety with no serious or severe adverse…
Read MoreA consortium led by Addex Therapeutics secures a €4 million Eurostars grant
The Geneva-based pharmaceutical company will use the grant to support its programme for mild neurocognitive disorders (mNCD). The project, called COGNI+, aims to develop clinical candidates ready for IND enabling studies and is led by a consortium that includes Naason Science (South Korea), BioAxis Research (Netherlands), Pharmidex Pharmaceutical Services (UK), and Stichting Radboud…
Read MoreMultiwave raises CHF 3.8 Million
Geneva-based deeptech startup Multiwave Technologies SA, led by Tryfon and Panos Antonakakis, is attracting new capital that will be dedicated to securing FDA approval for the world’s lightest portable magnetic resonance imaging (MRI) device. Swiss medical technology company Multiwave raised a total of CHF 3.8 million in two consecutive capital increases in July…
Read MoreSwiss Cancer Center Léman found a way to boost artificial immune cells to fight cancer
A team of Swiss researchers has discovered a way of prolonging the efficacy of CAR-T cells in immunotherapy for the treatment of certain blood cancers. CAR-T cells are T lymphocytes modified in the laboratory to specifically target cancer cells. However, their effectiveness rapidly diminishes in many patients. Researchers have identified a metabolic mechanism common…
Read More